O Brien Greene & Co. Inc Sells 105,006 Shares of The Joint Corp. $JYNT

O Brien Greene & Co. Inc lessened its holdings in shares of The Joint Corp. (NASDAQ:JYNT) by 63.1% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 61,454 shares of the company’s stock after selling 105,006 shares during the quarter. O Brien Greene & Co. Inc owned approximately 0.40% of Joint worth $586,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Nisa Investment Advisors LLC increased its stake in shares of Joint by 5,141.9% during the 2nd quarter. Nisa Investment Advisors LLC now owns 2,254 shares of the company’s stock worth $26,000 after purchasing an additional 2,211 shares during the last quarter. JPMorgan Chase & Co. boosted its holdings in Joint by 32.3% in the second quarter. JPMorgan Chase & Co. now owns 7,412 shares of the company’s stock worth $86,000 after purchasing an additional 1,810 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its position in Joint by 25.9% during the second quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 8,244 shares of the company’s stock worth $95,000 after buying an additional 1,698 shares during the last quarter. Stoneridge Investment Partners LLC acquired a new position in Joint during the third quarter worth $117,000. Finally, Rhumbline Advisers raised its holdings in Joint by 25.9% during the second quarter. Rhumbline Advisers now owns 20,934 shares of the company’s stock valued at $242,000 after buying an additional 4,307 shares in the last quarter. 76.88% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other Joint news, major shareholder Charles E. Jobson purchased 16,753 shares of the business’s stock in a transaction dated Friday, January 23rd. The stock was bought at an average cost of $10.00 per share, for a total transaction of $167,530.00. Following the completion of the acquisition, the insider directly owned 1,638,424 shares in the company, valued at $16,384,240. This represents a 1.03% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Over the last quarter, insiders purchased 60,849 shares of company stock valued at $542,411. Insiders own 27.90% of the company’s stock.

Analyst Upgrades and Downgrades

JYNT has been the subject of several recent analyst reports. Weiss Ratings reiterated a “sell (e+)” rating on shares of Joint in a research note on Thursday, January 22nd. B. Riley Financial lowered Joint from a “buy” rating to a “hold” rating in a report on Friday, November 7th. One investment analyst has rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average price target of $17.00.

Joint Stock Performance

Shares of NASDAQ:JYNT opened at $9.13 on Tuesday. The stock’s 50-day moving average is $9.30 and its 200-day moving average is $9.26. The company has a market cap of $135.73 million, a P/E ratio of -152.14 and a beta of 1.35. The Joint Corp. has a 52-week low of $7.50 and a 52-week high of $13.47.

Joint Company Profile

The Joint Chiropractic, Inc, doing business as Joint (NASDAQ: JYNT), is a franchisor and operator of outpatient chiropractic clinics in the United States. Under its flagship The Joint Chiropractic brand, the company offers membership-based, cash-focused spinal adjustment services designed to promote accessible, routine care for neck and back discomfort. By removing insurance requirements and offering walk-in visits, Joint aims to streamline the patient experience and reduce cost barriers to ongoing chiropractic treatment.

Joint’s growth strategy centers on partnering with franchisees to expand its network of clinics.